Bedrijfsoverzicht
Prestige Consumer Healthcare Inc. is a specialized manufacturer and distributor focused on over-the-counter health and personal care products, serving markets across North America, Australia, and internationally. The company operates within the Healthcare sector, specifically the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on producing non-prescription medications and consumer goods rather than prescription pharmaceuticals. With a market capitalization of $2.72 billion and annual revenue reaching $1.10 billion, the entity manages a workforce comprising 600 employees. These financial figures indicate that Prestige Consumer Healthcare Inc. holds a significant position within its niche, operating as a mid-to-large cap enterprise with substantial revenue generation capabilities relative to its employee base. The scale of the company, evidenced by its multi-billion dollar market cap and high revenue volume, suggests a mature business model with established distribution networks capable of sustaining operations across multiple geographic regions.
Financiële gezondheid
The company reported total revenue of $1.10 billion over the trailing twelve months, generating net income of $186.50 million and an EBITDA of $364.98 million. The substantial gap between the $1.10 billion in revenue and the $186.50 million in net income reveals a robust cost structure where operating expenses and taxes absorb approximately 83.1% of total sales before arriving at the bottom line. Free cash flow stands at $207.17 million, indicating that the company generates significant cash from its operations after capital expenditures, which provides substantial financial flexibility for debt servicing or strategic initiatives. The gross margin is 57.0%, reflecting high pricing power or low cost of goods sold typical in consumer health products. The operating margin of 29.1% demonstrates efficient management of operational costs, while the profit margin of 16.9% confirms the company's ability to convert a healthy portion of sales into actual earnings. On the liquidity front, cash holdings of $62.37 million are compared against total debt of $1.08 billion, resulting in a debt-to-equity ratio of 58.99. This high leverage ratio indicates that the balance sheet is leveraged, relying significantly on borrowed capital to fund its operations or growth. The current ratio of 3.11 suggests strong short-term liquidity, as current assets exceed current liabilities by a wide margin, ensuring the ability to meet short-term obligations without immediate distress. Regarding efficiency, the return on equity is 10.3% and the return on assets is 6.1%, metrics that reveal moderate effectiveness in generating returns relative to the capital invested by shareholders and the total asset base employed.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 14.92, while the forward P/E ratio is 11.76. The difference between these two metrics implies that the market expects earnings to decrease in the near future, as investors are willing to pay a lower multiple for anticipated future profits compared to current earnings. The price-to-book ratio stands at 1.46, indicating that the market values the company at a premium of 46% over its book value, suggesting confidence in the quality of its assets and brand equity. Alternative valuation metrics include a price-to-sales ratio of 2.46 and an EV/EBITDA of 10.12, which suggest the company is trading at a moderate multiple relative to its sales and earnings power before interest, taxes, depreciation, and amortization. The stock's recent trading range spans a 52-week high of $89.37 and a 52-week low of $51.24. Without a specific current price provided in the data, the valuation range indicates a significant volatility band of approximately $38.13 within the last year. The beta value is 0.47, which means the stock price exhibits significantly lower volatility relative to the broader market, making it less sensitive to general market fluctuations.
Growth & Income
Revenue growth over the last year was -2.4%, while earnings growth was -20.5%. The fact that earnings are declining at a much faster rate than revenue implies that the company is facing margin compression or one-time costs that are disproportionately affecting profitability compared to top-line performance. As the dividend yield is listed as N/A and the payout ratio is 0.0%, the company does not currently distribute dividends to shareholders. Instead, the company reinvests all of its earnings back into the business rather than paying dividends, a strategy often employed by companies seeking to fund growth or reduce debt without external financing. This non-dividend profile means the total return potential for investors relies entirely on capital appreciation rather than income distribution. Overall, the growth and income profile is characterized by a contraction in both revenue and earnings, with a complete absence of dividend income, pointing to a capital-intensive reinvestment phase or a period of market adjustment.